Compass Therapeutics, Inc. (CMPX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.78+2.92%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CMPX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -80.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
CMPX — earnings miss
Dated 2026-08-06
104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Compass Therapeutics, Inc. Date: August 6, 2026 By: /s/ Neil Lerner Neil Lerner Chief Accounting Officer
Why it matters: The FDA asked for a trial that shows a survival benefit before a BLA. Agreement on another path could keep the filing plan alive.
Supportive ifThe FDA agrees that Compass can submit a BLA without first running a new survival trial.
Worry ifThe FDA keeps its request for a new survival trial before any BLA submission.
Why it matters: Compass reported $180 million in cash and a runway into 2028. Higher costs can shorten that time.
Worry ifAt the Nov. 4 update, cash is below $180 million and management no longer states that it can fund operations into 2028.
Less concerning ifCash remains at or above $180 million, and management repeats its runway into 2028.
Why it matters: The study showed better response rates and longer time without cancer growth. The FDA's view of the survival data remains a key hurdle.
Worry ifESMO reports an ORR of 18.0% versus 5.3%, and median PFS of 4.7 versus 2.6 months. The FDA made no new demand beyond the stated survival-trial request.
Less concerning ifESMO data weaken the reported ORR or PFS results. Or the FDA says those results do not support a BLA without a new survival trial.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$260 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $620 loss on $10,000 · 6.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,883 loss on $10,000 · 88.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.